No article text was recorded for this version.
endocrine therapy resistance
Version 2 of 224 papers32 conceptsfrozen 2026-10-04
Papers in this version
- Blog: MYSM1 acts as a novel co-activator of ERα to confer antiestrogen resistance in breast cancer
- Blog: Targeting ESR1 mutation–induced transcriptional addiction in breast cancer with BET inhibition
- Blog: TRIM3 facilitates estrogen signaling and modulates breast cancer cell progression
- Blog: Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis
- Blog: Patritumab deruxtecan in HR+HER2− advanced breast cancer: a phase 2 trial
- Blog: Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation
- Blog: Loss function of tumor suppressor FRMD8 confers resistance to tamoxifen therapy via a dual mechanism
- Blog: Phage display screening identifies a novel peptide to suppress ovarian cancer cells in vitro and in vivo in mouse models
- Blog: PTK6 regulates growth and survival of endocrine therapy-resistant ER+ breast cancer cells
- Blog: Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort
- Blog: Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers
- Blog: SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients
- Blog: The SERM/SERD Bazedoxifene Disrupts ESR1 Helix 12 to Overcome Acquired Hormone Resistance in Breast Cancer Cells
- Blog: Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity
- Blog: Molecular Docking and 3D-Pharmacophore Modeling to Study the Interactions of Chalcone Derivatives with Estrogen Receptor Alpha
- Blog: Recombinant human erythropoietin plus all-trans retinoic acid and testosterone undecanoate for the treatment of anemia in patients with lower-risk myelodysplastic syndromes: a multicenter, single-arm, prospective trial
- Blog: Integrative analyses of gene expression and DNA methylation profiles in breast cancer cell line models of tamoxifen-resistance indicate a potential role of cells with stem-like properties
- Blog: RBP7 functions as a tumor suppressor in HR + breast cancer by inhibiting the AKT/SREBP1 pathway and reducing fatty acid
- Blog: Catalpol suppresses proliferation and facilitates apoptosis of MCF-7 breast cancer cells through upregulating microRNA-146a and downregulating matrix metalloproteinase-16 expression
- Blog: MiRNA-155 mediates TAM resistance by modulating SOCS6-STAT3 signalling pathway in breast cancer.
- Blog: Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers
- Blog: C-Cbl reverses HER2-mediated tamoxifen resistance in human breast cancer cells
- Blog: Retrospective analysis of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2), Ki67 changes and their clinical significance between primary breast cancer and metastatic tumors
- Blog: CCAR1 5′ UTR as a natural miRancer of miR-1254 overrides tamoxifen resistance
History & citation
Current · Permanent link
Cite this direction
Latest version (a living page):
@misc{lacuna_endocrine_therapy_resistance_5e781ff9,
title = {endocrine therapy resistance},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/endocrine-therapy-resistance/rdr_5e781ff935a84eb1b7f0c18b1ada476b},
note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-22},
}This exact version (version 2, frozen text):
@misc{lacuna_endocrine_therapy_resistance_5e781ff9_v2,
title = {endocrine therapy resistance},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/endocrine-therapy-resistance/rdr_5e781ff935a84eb1b7f0c18b1ada476b/v/2},
note = {Version 2, frozen 2026-10-04. Accessed 2026-11-22},
}